Hospital
ST Catherine Hospital INC
ST Catherine Hospital INC was paid $32.25M by Medicaid between Jan 2018 and Dec 2024, across 186 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoST CATHERINE HOSPITAL INC
EAST CHICAGO, IN 46312
EAST CHICAGO, IN 46312
33aNPI1689776882assigned 09/01/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$32.25M
24GClaims733,347
24DCodes billed186
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#12 of 69
Median peer was paid$9.76M
This provider vs. median3.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 118,480 | $2.16M | |
| 2019 | 88,434 | $3.05M | |
| 2020 | 66,593 | $2.74M | |
| 2021 | 104,483 | $4.89M | |
| 2022 | 138,316 | $7.02M | |
| 2023 | 123,381 | $6.91M | |
| 2024incomplete | 93,660 | $5.47M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 36,046 | 30,573 | $5.81M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 32,317 | 28,546 | $5.75M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.4% | 18,353 | 15,390 | $2.70M |
| 71045 | Radiologic examination, chest; single view | 6.1% | 15,350 | 12,594 | $1.98M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4.5% | 21,930 | 17,830 | $1.44M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.5% | 9,395 | 8,544 | $1.14M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.4% | 14,870 | 2,687 | $1.08M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 3.3% | 511 | 400 | $1.07M |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.5% | 11,802 | 10,173 | $812K |
| 71046 | Radiologic examination, chest; 2 views | 2.4% | 5,876 | 5,041 | $787K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.1% | 691 | 513 | $682K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.0% | 7,552 | 4,203 | $633K |
174 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 3,215 | $519K |
| 99232 | Hospital visit by a doctor, follow-up day | 1.6% | 1,711 | $514K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.5% | 2,306 | $497K |
| 80050 | General health panel | 1.4% | 2,889 | $436K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 3,319 | $384K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.1% | 2,549 | $350K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,039 | $313K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,863 | $309K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 716 | $269K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 58,449 | $237K |
| 80053 | Comprehensive metabolic panel | <1% | 41,263 | $233K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14,267 | $231K |
| 87631 | <1% | 2,947 | $223K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 104,616 | $205K |
| 90899 | <1% | 1,622 | $198K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 15,194 | $187K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,405 | $157K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,386 | $156K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 886 | $156K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 10,042 | $128K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,460 | $124K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,659 | $121K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,966 | $120K |
| 80061 | Lipid panel | <1% | 14,293 | $117K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,262 | $111K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 25,207 | $107K |
| 81025 | <1% | 19,332 | $105K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 485 | $102K |
| 84484 | <1% | 10,176 | $89K | |
| 92557 | <1% | 801 | $88K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,498 | $82K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 82 | $75K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 258 | $69K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 307 | $67K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 29 | $64K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,128 | $63K |
| 81001 | <1% | 29,924 | $58K | |
| 85027 | <1% | 14,323 | $53K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,160 | $53K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 48 | $49K |
| 99220 | <1% | 300 | $46K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 311 | $43K |
| 83735 | <1% | 12,213 | $39K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,541 | $37K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,456 | $37K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 6,756 | $36K |
| 83690 | <1% | 10,221 | $35K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 380 | $33K |
| 95811 | <1% | 21 | $32K | |
| 92567 | <1% | 1,318 | $29K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,835 | $26K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,803 | $25K |
| 80076 | <1% | 5,476 | $24K | |
| 88142 | <1% | 2,207 | $24K | |
| 76818 | <1% | 253 | $22K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,048 | $22K |
| 73560 | <1% | 637 | $20K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 849 | $20K |
| 96523 | <1% | 386 | $17K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 807 | $17K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 836 | $17K |
| 83880 | <1% | 856 | $14K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 87 | $14K |
| 73564 | <1% | 255 | $14K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,238 | $14K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,747 | $13K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 76 | $13K |
| 86780 | <1% | 989 | $12K | |
| 83970 | <1% | 684 | $12K | |
| 83655 | <1% | 949 | $12K | |
| 97010 | <1% | 650 | $11K | |
| 82728 | <1% | 1,457 | $11K | |
| 82607 | <1% | 983 | $11K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 920 | $10K |
| 84439 | <1% | 1,195 | $10K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,549 | $10K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 63 | $9K |
| 82043 | <1% | 2,343 | $9K | |
| 97161 | <1% | 150 | $8K | |
| 80074 | <1% | 167 | $7K | |
| 96376 | <1% | 2,323 | $7K | |
| 87150 | <1% | 228 | $7K | |
| 83550 | <1% | 1,445 | $7K | |
| 73630 | <1% | 172 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 669 | $7K |
| 85610 | <1% | 3,518 | $7K | |
| 85730 | <1% | 2,242 | $6K | |
| 83540 | <1% | 1,507 | $5K | |
| 82570 | <1% | 1,376 | $5K | |
| 86850 | <1% | 834 | $5K | |
| 86762 | <1% | 360 | $5K | |
| 87340 | <1% | 565 | $4K | |
| 96417 | <1% | 52 | $3K | |
| 70486 | <1% | 14 | $3K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 61 | $3K |
| 84702 | <1% | 374 | $3K | |
| 93017 | <1% | 32 | $3K | |
| 87807 | <1% | 211 | $3K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 24 | $3K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 120 | $2K |
| 82077 | <1% | 213 | $2K | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 261 | $2K |
| 84100 | <1% | 945 | $2K | |
| 86901 | <1% | 807 | $2K | |
| 86900 | <1% | 780 | $2K | |
| 86140 | <1% | 721 | $2K | |
| 82947 | <1% | 626 | $2K | |
| 97162 | <1% | 16 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 30 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 38 | $1K |
| 73030 | <1% | 34 | $1K | |
| 85652 | <1% | 735 | $1K | |
| 96367 | <1% | 61 | $1K | |
| 73502 | <1% | 17 | $937.33 | |
| 74022 | <1% | 13 | $914.60 | |
| 87040 | <1% | 72 | $854.50 | |
| 87808 | <1% | 90 | $769.62 | |
| 80069 | <1% | 173 | $761.86 | |
| 83605 | <1% | 96 | $739.10 | |
| 70360 | <1% | 12 | $680.04 | |
| 85379 | <1% | 119 | $665.46 | |
| 72100 | <1% | 28 | $656.02 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 58 | $615.76 |
| 97116 | <1% | 81 | $559.38 | |
| 84145 | <1% | 30 | $540.32 | |
| 87081 | <1% | 86 | $503.92 | |
| 84550 | <1% | 155 | $441.82 | |
| 92588 | <1% | 12 | $372.92 | |
| 87210 | <1% | 134 | $323.31 | |
| 84153 | <1% | 26 | $284.65 | |
| 82950 | <1% | 62 | $283.83 | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 40 | $277.50 |
| 82962 | <1% | 226 | $250.48 | |
| 84156 | <1% | 90 | $228.27 | |
| 83615 | <1% | 77 | $205.85 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 13 | $198.45 |
| 82565 | <1% | 111 | $188.95 | |
| 82105 | <1% | 12 | $186.46 | |
| 85018 | <1% | 210 | $174.89 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,096 | $170.50 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,289 | $88.58 |
| 84207 | <1% | 15 | $70.74 | |
| 82550 | <1% | 16 | $70.20 | |
| 87077 | <1% | 27 | $58.98 | |
| 82746 | <1% | 17 | $56.43 | |
| 87186 | <1% | 26 | $54.50 | |
| 86592 | <1% | 41 | $51.63 | |
| G0378 | Hospital observation service, per hour | <1% | 85 | $17.14 |
| 85014 | <1% | 142 | $13.73 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,575 | $6.07 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,323 | $4.82 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 1,301 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 956 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 81 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 49 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 272 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 13 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 14 | $0.00 |
| 77003 | 0% | 15 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 170 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 54 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 26 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 16 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 480 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 663 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 279 | $0.00 |
| C1769 | Guide wire | 0% | 56 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 412 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 34 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 403 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 40 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 71 | $0.00 |
| 36591 | 0% | 22 | $0.00 | |
| 84703 | 0% | 44 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKULLERSTRAND, CHAR (REGIONAL DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Munster Medical Research Foundation INC | Munster, IN | $23.67M |
| ST Mary Medical Center INC | Hobart, IN | $23.44M |
| ST Catherine Hospital INC | East Chicago, IN | $198K |
| Munster Medical Research Foundation INC | Munster, IN | $50K |
| ST Mary Medical Center INC | Hobart, IN | $19K |
| Community Stroke and Rehabilitation Center INC | Crown Point, IN | $3K |
| ST Catherine Hospital INC | East Chicago, IN | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.